Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

Without a specific tailored Long COVID therapy, individualized treatment based on patient phenotypes, along with extensive evaluations, is essential for effective symptom management.


Exploring The Challenges and Insights in Long COVID Treatment and Management

Articles

A clinician’s guide to using a personalized medicine approach to monitor cognition in MS.

Holistic Personalized Care for Patients with Multiple Sclerosis and the Importance of Cognitive Monitoring

Melissa Spencer, PhD, gave commentary on her presentation from AANEM 2024, highlighting the emerging role of adeno-associated virus as a delivery system for gene therapies targeting muscular dystrophies.

AAV Vectors in Gene Therapy: Overcoming Barriers for Muscular Dystrophy Treatment

The professor of neurology at NYU Grossman School of Medicine discussed the results of a phase 2b study on XEN1101, an investigational drug in development for focal epilepsy. [WATCH TIME: 4 minutes]

Overviewing Positive Phase 2 Data on Potassium Channel Inhibitor XEN1101: Jacqueline French, MD

Professor, department of neurology, NYU Langone Health Center, and codirector, Epilepsy Clinical Trials, NYU Langone, Comprehensive Epilepsy Center; founder/director, Epilepsy Study Consortium.

Assistant professor of neurology at University of Colorado School of Medicine.

As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Sana Aslam, DO, an assistant professor of neurology at University of Colorado School of Medicine. 

NeurologyLive® Clinician of the Month Spotlight: Sana Aslam, DO

Vice President of Public Policy and Advocacy, Muscular Dystrophy Association (MDA)

Prior to the 2025 MDA Conference, the vice president of Public Policy & Advocacy at the Muscular Dystrophy Association talked about the increasing interest in gene therapy in the field of neuromuscular diseases.

The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP

The professor of neurology at NYU Grossman School of Medicine provided clinical insight on the uniqueness of investigational XEN1101 and the idea behind potassium channel inhibitors to treat epilepsy. [WATCH TIME: 3 minutes]

Mechanism and Promise Behind XEN1101 in Focal Epilepsy: Jacqueline French, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AANEM 2024

CTAD 2024

MDS 2024

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

New research found over a quarter of children with treatment-refractory epilepsy sustained treatment response to CBD over four years.

Clinical

Long-term Efficacy of Cannabidiol in Children With Epilepsy